Q-omics provides the consensus-scored GTF3C6P2 profile across patient tissues and cancer cell-line models. GTF3C6P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GTF3C6P2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, GTF3C6P2 RNA expression shows 7,841 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, COAD, and THYM as cancer lineages where GTF3C6P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF3C6P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF3C6P2 survival associations across molecular data types. GTF3C6P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF3C6P2 RNA expression–survival associations across cancer types. High GTF3C6P2 expression shows unfavorable associations in LIHC and SKCM, but favorable associations in OV, STAD, BLCA and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GTF3C6P2 RNA expression.
This table summarizes GTF3C6P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GTF3C6P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF3C6P2 shows higher tumor expression in COAD, LUSC, BLCA, LUAD, BRCA and KIRC. The COAD box plot shows higher GTF3C6P2 RNA expression in tumor versus normal tissue (log2 FC = +0.417, t-test p < 0.001).
This table shows molecular features associated with GTF3C6P2 in patient tissues and cancer cell lines. In patient samples, GTF3C6P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
